[
  {
    "cluster": 1,
    "content": "TITLE: Item 5.02\nTEXT: Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Scott Gottlieb, M.D. as independent director Appointment of Scott Gottlieb, M.D. as independent director On November 18, 2025, UnitedHealth Group Incorporated (the “Company”) announced the appointment of Scott Gottlieb, M.D. to serve as an independent director of the Company, effective immediately. Dr. Gottlieb has not yet been appointed to any committees of the Board of Directors. On November 18, 2025, UnitedHealth Group Incorporated (the “Company”) announced the appointment of Scott Gottlieb, M.D. to serve as an independent director of the Company, effective immediately. Dr. Gottlieb has not yet been appointed to any committees of the Board of Directors. Dr. Gottlieb served as FDA commissioner from 2017 to 2019, where he became known for promoting transparency, strengthening patient safety and widening consumer choice. He led initiatives to modernize regulations to help foster medical innovation, promote competition in the pharmaceutical market, confront the opioid epidemic and curb youth tobacco use. Dr. Gottlieb served as FDA commissioner from 2017 to 2019, where he became known for promoting transparency, strengthening patient safety and widening consumer choice. He led initiatives to modernize regulations to help foster medical innovation, promote competition in the pharmaceutical market, confront the opioid epidemic and curb youth tobacco use. In addition to his FDA service, Dr. Gottlieb has held roles at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee. A physician, he is an elected member of the National Academy of Medicine and serves as a senior fellow at the American Enterprise Institute and a partner at New Enterprise Associates. He also contributes to CNBC and CBS News. In addition to his FDA service, Dr. Gottlieb has held roles at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee. A physician, he is an elected member of the National Academy of Medicine and serves as a senior fellow at the American Enterprise Institute and a partner at New Enterprise Associates. He also contributes to CNBC and CBS News. Dr. Gottlieb also serves as a director of Pfizer, Inc., Tempus AI, Inc. and Illumina, Inc. Dr. Gottlieb also serves as a director of Pfizer, Inc., Tempus AI, Inc. and Illumina, Inc. Dr. Gottlieb will receive compensation for his services as a director in accordance with the Company’s standard compensation program for non-employee directors as amended from time to time, the material terms of which are described in the Company’s 2025 proxy statement. Dr. Gottlieb will receive compensation for his services as a director in accordance with the Company’s standard compensation program for non-employee directors as amended from time to time, the material terms of which are described in the Company’s 2025 proxy statement. In accordance with the Company’s customary practice, the Company is entering into its standard form of indemnification agreement with Dr. Gottlieb, which requires the Company to indemnify him against certain liabilities that may arise as a result of his status or service as a director. The foregoing description is qualified in its entirety by the full text of the form of Indemnification Agreement, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 1, 2015. In accordance with the Company’s customary practice, the Company is entering into its standard form of indemnification agreement with Dr. Gottlieb, which requires the Company to indemnify him against certain liabilities that may arise as a result of his status or service as a director. The foregoing description is qualified in its entirety by the full text of the form of Indemnification Agreement, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 1, 2015. There are no arrangements or understandings between Dr. Gottlieb and any other person pursuant to which Dr. Gottlieb was appointed to serve on the Board of Directors. Dr. Gottlieb has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Gottlieb and any other person pursuant to which Dr. Gottlieb was appointed to serve on the Board of Directors. Dr. Gottlieb has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 21, 2025 Date: November 21, 2025 UNITEDHEALTH GROUP INCORPORATEDBy: /s/ Kuai H. LeongKuai H. LeongSenior Deputy General Counsel and Deputy Corporate Secretary UNITEDHEALTH GROUP INCORPORATEDBy: /s/ Kuai H. LeongKuai H. LeongSenior Deputy General Counsel and Deputy Corporate Secretary UNITEDHEALTH GROUP INCORPORATEDBy: /s/ Kuai H. LeongKuai H. LeongSenior Deputy General Counsel and Deputy Corporate Secretary UNITEDHEALTH GROUP INCORPORATED UNITEDHEALTH GROUP INCORPORATED UNITEDHEALTH GROUP INCORPORATED UNITEDHEALTH GROUP INCORPORATED By: /s/ Kuai H. Leong Senior Deputy General Counsel and Deputy Corporate Secretary Senior Deputy General Counsel and Deputy Corporate Secretary Senior Deputy General Counsel and Deputy Corporate Secretary\n"
  }
]